Immunovia ABIMMVF -61.59%44 Net Current Asset Value is $0.01 as of Mar. 2026, which is 100% below its 10-year median of 7.25. GuruFocus rates IMMVF with a GF Score™ of 44/100 and a GF Value™ of $0.01. The stock has 4 warning signs investors should review. Among 100 Medical Diagnostics & Research companies, Immunovia AB ranks better than 60% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Immunovia AB's net current asset value per share for the quarter that ended in Mar. 2026 was $0.01.
The historical rank and industry rank for Immunovia AB's Net Current Asset Value or its related term are showing as below:
IMMVF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.61 Med: 7.25 Max: 20.73
Current: 2
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Immunovia AB was 20.73. The lowest was 0.61. And the median was 7.25.
IMMVF's Price-to-Net-Current-Asset-Value is ranked better than 60% of 100
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.865
vs IMMVF: 2.00
Immunovia AB (OTCPK:IMMVF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Immunovia AB Net Current Asset Value Related Terms
Immunovia AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Immunovia AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMMVF vs TMO, DHR, IDXX: Net Current Asset Value Comparison
For the Diagnostics & Research subindustry, Immunovia AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovia AB Price-to-Net-Current-Asset-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Immunovia AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.01 mean?
Immunovia AB (IMMVF) has a Net Current Asset Value of $0.01 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Immunovia AB and its competitors. This is 100% below median its historical median of 7.25. Over the past decade, Immunovia AB's Net Current Asset Value has ranged from 0.61 to 20.73. According to the industry distribution chart, Immunovia AB ranks #40 out of 100 companies in the Medical Diagnostics & Research industry, placing it in the top 40%.
Is Immunovia AB's Net Current Asset Value too high?
Immunovia AB's current Net Current Asset Value of $0.01 is 100% below median its 10-year median of 7.25. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 20.73. The Medical Diagnostics & Research industry median Net Current Asset Value is 3.87. Immunovia AB's value of $0.01 is 99.7% below this industry median. Based on the distribution chart, Immunovia AB ranks #40 out of 100 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Immunovia AB has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Net Current Asset Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #40 out of 100 companies for Net Current Asset Value. This puts Immunovia AB in the upper half of its industry. The industry median Net Current Asset Value is 3.87. Immunovia AB's value of $0.01 is 99.7% below this benchmark. Historically, Immunovia AB's own Net Current Asset Value has ranged from 0.61 to 20.73 over the past decade. While the company's 10-year median is 7.25 vs. the industry median of 3.87, Immunovia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Diagnostics & Research company?
The median Net Current Asset Value among Medical Diagnostics & Research companies is 3.87, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunovia AB's current Net Current Asset Value of $0.01 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Immunovia AB and its competitors. For the Medical Diagnostics & Research industry, the median Net Current Asset Value is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovia AB's current Net Current Asset Value is $0.01, which is 100% below median its own 10-year median of 7.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current Net Current Asset Value of $0.01. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Net Current Asset Value is $0.01, which is 100% below median its 10-year median of 7.25 and 99.7% below the Medical Diagnostics & Research industry median of 3.87. Immunovia AB's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current Net Current Asset Value is $0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (IMMVF) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued.
The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.
Key valuation signals for IMMVF:
Net Current Asset Value: $0.01 (100% below median its 10-year median of 7.25)
GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
Industry Position: 99.7% below the Medical Diagnostics & Research median (#40 of 100)
No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
44GF Score
Get the complete analysis for IMMVF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMVF has been successfully added to your 
